The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Objective metrics of patient activity: Use of wearable trackers and patient reported outcomes in predicting unexpected healthcare events in cancer patients undergoing highly emetogenic chemotherapy.
 
Alexander S. Martin
No Relationships to Disclose
 
Roger Wilson Boles
No Relationships to Disclose
 
Luciano Nocera
No Relationships to Disclose
 
Anand Kolatkar
Stock and Other Ownership Interests - Epic Sciences
Patents, Royalties, Other Intellectual Property - HD-SCA technology was developed by myself and members of my team while at The Scripps Research Institute, which has subsequently licensed the technology to Epic Sciences for exclusive commercial development.
 
Marcella May
No Relationships to Disclose
 
Zaki Hasnain
No Relationships to Disclose
 
Naoto T. Ueno
Honoraria - Kyowa Hakko Kirin
Research Funding - Amgen; Bayer; Bio-Path Holdings; Celgene; Daiichi Sankyo; GlaxoSmithKline; Kyowa Hakko Kirin; Medivation; Merck; Novartis; Puma Biotechnology
Travel, Accommodations, Expenses - Kyowa Hakko Kirin
 
Sriram Yennu
Research Funding - Bayer (Inst); Genentech/Roche (Inst); Helsinn Therapeutics (Inst)
 
Angela Alexander
No Relationships to Disclose
 
Aaron Mejia
No Relationships to Disclose
 
Ming Li
No Relationships to Disclose
 
Frankie A. Cozzens Philips
No Relationships to Disclose
 
Paul K. Newton
No Relationships to Disclose
 
Joan Broderick
No Relationships to Disclose
 
Cyrus Shahabi
No Relationships to Disclose
 
Peter Kuhn
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Epic Sciences; Fluidigm; Novartis
Research Funding - Abbvie; Amgen; Daiichi Sankyo; Fluidigm; Gilead Sciences; Kite, a Gilead company; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - HD-SCA technology was developed by myself and members of my team while at The Scripps Research Institute, which has subsequently licensed the technology to Epic Sciences for exclusive commercial development.
Expert Testimony - BDMK Law
 
Jorge J. Nieva
Consulting or Advisory Role - AstraZeneca; Genentech/Roche; Turnstone Bio
Research Funding - Merck